Home › Diffuse Large B-Cell Lymphoma › North Dakota
Pag-aaral pangklinika para sa Diffuse Large B-Cell Lymphoma sa North Dakota
4 pag-aaral para sa Diffuse Large B-Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa North Dakota.
Mga Lungsod sa North Dakota
Opisyal na teksto ng pag-aaral (English)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Essentia Health Cancer Center-South University Clinic, Fargo
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06649812A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Sanford Health Roger Maris Cancer Center ( Site 0189), Fargo
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06717347Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo
Nagre-recruitPhase 1/2
6 Months – 25 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06395103Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 2, 2026 · NCT05633615Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.